MolecuLight Receives Innovative Technology Contract from Vizient for its i:X® Fluorescence Wound Imaging Device Protection Status
Blog Category: 

Industry News

May 4, 2021 – Pittsburgh, PA – MolecuLight Corp., creator of a point-of-care fluorescence imaging device for detection of wounds containing elevated bacterial loads, announces its MolecuLight i:X® fluorescence wound imaging device has received an Innovative Technology contract from Vizient, Inc., the nations’ largest member-driven health care performance improvement company. The new Innovative Technology contract for MolecuLight i:X signifies to Vizient members the device’s unique qualities that potentially bring improvement to the health care industry.

Innovative Technology contracts are awarded based on the recommendations of health care experts serving on a Vizient member-led council who review potentially innovative products and identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety or improve business operations of health care organizations.

The MolecuLight i:X performs digital wound area measurement, allowing for the accurate documentation of wounds. It is the only point-of-care imaging device that allows clinicians to visualize elevated bacterial burden (>104 CFU/g) in wounds, along with clinical signs and symptoms (CSS). As the presence of elevated bacterial burden precludes wounds from healing,1 having a point-of-care device such as the i:X provides invaluable information in real-time to inform clinician decision-making. Published results from a recent 350-patient, 14-site study showed that the clinical standard of care use (CSS) only detected 15% of wounds with elevated bacterial burden, while addition of the i:X to standard of care led to a 400% improvement in detecting these wounds.2

“We are honored to have our MolecuLight i:X point-of-care device awarded an Innovative Technology contract,” says Anil Amlani, MolecuLight’s CEO. “Through i:X, we hope to enable significant cost-savings and improvement in clinical outcomes through informing clinicians on the presence of elevated bacterial burden in wounds. As the i:X has now been added on contract with Vizient Inc., we are now more accessible to the extensive Vizient member base. This includes more than 50% of acute care providers in the US, including 95% of US academic medical centers and more than 20% of ambulatory providers. These institutions can now easily access the i:X platform through the contract and quickly see the clinical benefits in their wound care practices.”

“The Vizient Innovative Technology Exchange offers suppliers the opportunity to demonstrate their products and gain direct feedback from hundreds of hospital experts who attend the annual event. Congratulations to MolecuLight on receiving this status, based on the recommendation of the member council,” said Debbie Archer, director of procurement and Vizient Innovative Technology Program leader.

1. Caldwell et al. Surg Clin North Am, 2020, 100(4)
2. Le et al. Adv Wound Care, 2021

About MolecuLight
MolecuLight is the manufacturer of MolecuLight i:X®, a real-time handheld fluorescence imaging device.

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.

Recommended for You

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.